The 6 analysts offering 12-month price forecasts for Eiger BioPharmaceuticals Inc have a median target of 25.50, with a high estimate of 49.00 and a low estimate of 22.00. The median estimate represents a +191.43% increase from the last price of 8.75.
The current consensus among 6 polled investment analysts is to Buy stock in Eiger BioPharmaceuticals Inc. This rating has held steady since March, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share $0.19
Reporting Date Mar 18
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.